Clinical trials: Conversion Disorder
- Condition Conversion Disorder
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Epilepsy
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures
The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are withdrawn from 1 to 2 marketed antiepileptic…
- Trial name
- ALEX-MT (NCT00520741)
- Testing
- Lacosamide
- Where
- 158 sites in United States, Australia and 11 more
- Volunteers
- 426 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Epilepsy
Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy
This study includes patients 16 years of age or older with a confident diagnosis of epilepsy who are currently treated with an antiepileptic drug (AED) monotherapy but require a change in therapy due to inadequate seizure control…
- Trial name
- NCT00043914
- Testing
- lamotrigine
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Epilepsy, Partial-onset Seizures
A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures
This study is to evaluate the long-term safety and tolerability of Lacosamide (LCM) 200 mg/day to LCM 600 mg/day taken in monotherapy in Japanese subjects who currently have partial-onset seizures with or without secondary…
- Trial name
- NCT02124564
- Testing
- Lacosamide
- Where
- 11 sites in Japan
- Volunteers
- 19 people
- Sponsor
- UCB Japan Co. Ltd.
Epilepsy
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
Antiepileptic Drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy.
- Trial name
- NCT00699283
- Testing
- Brivaracetam
- Where
- 68 sites in United States, France and 4 more
- Volunteers
- 62 people
- Sponsor
- UCB Pharma
Epilepsy, Partial
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.
- Trial name
- NCT00355082
- Testing
- lamotrigine, 300 mg/day, lamotrigine, 250 mg/day
- Where
- 103 sites in United States, Argentina and 6 more
- Volunteers
- 226 people
- Sponsor
- GlaxoSmithKline
Epilepsy
Conversion to Monotherapy Study With Keppra XR for Partial Seizures
The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.
- Trial name
- NCT00419094
- Testing
- Keppra XR
- Where
- 45 sites in United States, Mexico and 2 more
- Volunteers
- 228 people
- Sponsor
- UCB Pharma
Epilepsy
Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy
A cohort of patients who became seizure-free during add-on treatment to one standard AED with Keppra in a previous trial (N01031) were followed to assess whether seizure freedom was maintained. Tolerability was documented.
- Trial name
- NCT00630357
- Testing
- Levetiracetam (Keppra)
- Volunteers
- 14 people
- Sponsor
- UCB Pharma
Anemia of Chronic Kidney Disease
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease
This study will assess the safety and efficacy of once daily dosing of vadadustat for the treatment of pediatric participants with anemia of Chronic Kidney Disease (CKD) after conversion from an Erythropoiesis Stimulating Agent…
- Trial name
- CONVERSION (NCT05082571)
- Testing
- vadadustat
- Where
- United States
- Sponsor
- Akebia Therapeutics
Epilepsy
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
Antiepileptic drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy.
- Trial name
- NCT00698581
- Testing
- Brivaracetam
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 88 people
- Sponsor
- UCB Pharma
Hemophilia B
Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX
The purpose of this study is to collect data around the period of the conversion from plasma-derived Factor IX (pdFIX) to BeneFIX.
- Trial name
- NCT00749476
- Testing
- Factor IX recovery
- Where
- 8 sites in France
- Volunteers
- 1 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Epilepsy
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
Pharmacokinetic (PK) study to characterize changes in serum concentrations in epilepsy patients when switching from LAMICTAL immediate-release to extended-release and vice versa.
- Trial name
- NCT00264615
- Testing
- lamotrigine extended-release
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline